Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

vituximab toward later-stage clinical trials. Planning for this exciting next phase for our bavituximab oncology program has already begun."

Mr. King added, "This past year we also made significant advancements in our bavituximab and broader anti-PS anti-viral program, receiving high-profile international validation through the publication of data in the highly respected scientific journal Nature Medicine, which confirmed the anti-viral potential of bavituximab and our other anti-PS antibodies. We were also successful in completing contract negotiations with the DTRA, allowing us to expand the evaluation of our anti-PS antibodies as potential broad spectrum agents for the treatment or prevention of viral hemorrhagic fever virus infections. This contract directly or indirectly supports our bavituximab and other anti-PS technology programs and represents another significant validation for the anti-PS technology platform."

Mr. King continued, "Our Cotara clinical program continues to advance with patient enrollment nearing completion in our dose confirmation and dosimetry study in patients with recurrent glioblastoma (GBM), and enrollment exceeds the halfway mark in our Phase II trial in relapsed GBM patients. We recently presented dosimetry study data at the Society of Nuclear Medicine 2009 Annual Meeting, further confirming that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs, reinforcing its potential as a possible new treatment for GBM."

At April 30, 2009, Peregrine had $10 million in cash and cash equivalents, compared to $15.1 million in cash and cash equivalents at April 30, 2008. After the close of the 2009 fiscal year, Peregrine raised approximately $6.9 million in gross proceeds from the sale of common stock from its existing shelf registration. The stock was sold in an "At the Market" offering as defined in Rule 415
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
(Date:12/17/2014)... Amy Norton HealthDay ... Yoga has long been believed to improve overall health, but ... also help the heart, a new review finds. In ... such as brisk walking, said lead researcher Paula Chu, a ... The review, of 37 clinical trials, found that people ...
(Date:12/15/2014)... December 15, 2014 Veretekk.com, Inc. announced ... Ocean Avenue. JM Ocean Avenue has secured exclusive ... online automated marketing system. JM Ocean Avenue is ... merger of Ocean Avenue and JM International, with partial ... Billion per year company. , “After nearly 2 decades ...
(Date:12/15/2014)... OutMarket , a provider of marketing automation ... Sheets ,” a guide that exposes the insider secrets ... top ten social media networks. , Social media ... and customer service. It can also increase new leads ... new networks and weather constantly changing algorithms, they need ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... Associations Los Angeles Division today will honor John Michael ... use around the country and one of the outstanding ... Medical Center (LA BioMed). , The association will present ... and William Koenig, Los Angeles County Emergency Medical Services ...
... Combe Incorporated Introduces Pesticide-Free Treatment that Safely ... Eliminates Head Lice, Eggs and Nits, WHITE PLAINS, ... contagious conditions among children, only second to the common,cold.(1) There are ... to miss approximately 12 to 24 million school days annually.(3),But, now ...
... 3, 2008 A new study presented ... by researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) ... Vitamin C with,Bioperine(R), provides 275 percent faster ... Reece, President of Scientific Food Solutions said, ...
... as probable causes , , THURSDAY, April 3 (HealthDay News) ... apparently the result of being exposed to anesthetic gases, ... new study found. , Not only do veterinarians need ... offices and labs need to be managed better, the ...
... Uroplasty, Inc.,(Amex: UPI ), a medical device company ... treatment of voiding,dysfunction, today announced plans to double its ... which began on April 1, 2008., "We have ... the U.S. and in fiscal 2008 built a domestic,sales ...
... switch provider sees telcos looking to find,viable solutions for improving public safety and network resiliency for all ... Americans, BOULDER, Colo., April 3, 2008 , ... CEO Aztek Networks ( http://www.azteknetworks.net ), ... 20 years experience, Bruny has served as CEO of ...
Cached Medicine News:Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 2Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 3Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Women Veterinarians Face Higher Miscarriage Risk 2Health News:Women Veterinarians Face Higher Miscarriage Risk 3Health News:Uroplasty Plans to Double Sales Force During Fiscal 2009 2Health News:Uroplasty Plans to Double Sales Force During Fiscal 2009 3Health News:Uroplasty Plans to Double Sales Force During Fiscal 2009 4Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 2Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 3
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO ... Quantum Materials Corp (OTCQB:QTMM), will be speaking ... Quantum Materials (RCQM) on December 16th, 2014. The RCQM ... exotic nanomaterials in attracting top faculty and students and ... collaborate on research. "We have a ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and Markets ... addition of the "Drug Injection Devices to ... http://photos.prnewswire.com/prnh/20130307/600769 As ... an expanding list of health conditions, drug developers ... simplify the administration process and increase the efficiency ...
(Date:12/13/2014)... DUBLIN , December 12, 2014 /PRNewswire/ ... ) has announced the addition of the  ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... dioxide (CO2) in the respiratory gasses during ... respiratory care. Capnography provides information about CO2 ...
Breaking Medicine Technology:Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 2Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 3
... PRGO ; TASE) today announced that it ... of the assets of CanAm Care, a privately-held, Alpharetta, ... million in cash. The acquisition is expected to be ... The assets acquired from CanAm Care include: Dex4® hypoglycemia ...
... 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, today announced updates on new product launches for ... in 2012. N ew product ... new products, exceeding its product development goals outlined at the ...
Cached Medicine Technology:Perrigo Acquires Assets of CanAm Care for $36 Million 2Perrigo Acquires Assets of CanAm Care for $36 Million 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 2Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 4
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: